Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label aftercare treatment with Lamazym in alpha-mannosidosis
2013-000336-97Phase 3Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Dec 2014
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of velmanase alfa in alpha-mannosidosis, sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Long-term safety of Lamazym. Started Dec 2014; status: completed.
02
Drugs
velmanase alfa
03
Conditions
alpha-mannosidosis
Beyond the preview
Go deeper on 2013-000336-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000336-97.